Condensed Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue:
Total revenue	$ 1,935	$ 8,093
Operating expenses:
Research and development	19,131	33,536
General and administrative	6,365	4,558
Total operating expenses	25,496	38,094
Operating loss	(23,561)	(30,001)
Other income, net	260	957
Loss before benefit from income taxes	(23,301)	(29,044)
Benefit from income taxes	0	122
Net Loss	$ (23,301)	$ (28,922)
Net Loss per share:
Basic and Diluted	$ (0.47)	$ (0.62)
Weighted average shares:
Basic and Diluted	49,917,990	46,724,951
Other comprehensive loss, net of tax of $0:
Change in unrealized gains (losses) on available-for-sale marketable securities	$ (61)	$ (238)
Total comprehensive loss	(23,362)	(29,160)
License and Milestone Fees
Revenue:
Total revenue	1,192	8,021
Collaborative Revenue
Revenue:
Total revenue	706
Clinical Compound Revenue
Revenue:
Total revenue	$ 37	$ 72